Does tryptophan affect how well triptans relieve migraine?
Official title: Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Run by University Hospital, Clermont-Ferrand · NCT07177885 · Data updated 2026-11-12
This test sees if tryptophan levels and their by-products influence how well triptans relieve migraine attacks in adults who have been identified as triptan responders or non-responders.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 144 (estimated) |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Status | Recruiting |
| Started | March 5, 2026 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT07177885 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–50 with a clinical diagnosis of migraine who have been classified as triptan responders or non-responders, including cisgender men and premenopausal cisgender women, and who are affiliated with a social security system.
✕Probably not a fit
Pregnant or breastfeeding people, those outside the 18–50 age range, or people without a known triptan response classification are unlikely to benefit from this study's findings or are excluded from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect blood samples to compare tryptophan and its metabolic by-products (including serotonin and kynurenine pathway metabolites) between adults who respond to triptans and those who do not. Participants are adults aged 18–50, including cisgender men and premenopausal cisgender women, diagnosed with migraine per ICHD-3 and classified by triptan response. The protocol also examines whether conditions that impair intestinal absorption (for example inflammatory bowel disease or diabetes) relate to altered tryptophan levels and triptan resistance. No drug interventions are given as part of the protocol; the main procedure is blood collection and metabolic analysis at CHU de Clermont-Ferrand.
Why it matters
Potential benefit: If successful, the findings could help tailor migraine treatments by identifying patients less likely to benefit from triptans and suggesting alternative approaches.
How similar studies have gone: There are no prior clinical studies directly linking tryptophan status to triptan effectiveness, though preclinical data suggest that low-tryptophan diets can reduce sumatriptan effectiveness.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cisgender women, premenopausal, aged 18 to 50 years. * Cisgender men, aged 18 to 50 years. * Diagnosed with migraine (according to ICHD-3 criteria). * Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022). * Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics). * All routes of administration and all dosages. * Affiliation with a social security system. Exclusion Criteria: * Patients under guardianship, curatorship, deprivation of liberty, or legal protection * Pregnant and breastfeeding women
Where it's running
-
CHU de Clermont-Ferrand
Clermont-Ferrand, France Recruiting
Study contacts
- Principal investigator: Xavier Moisset — University Hospital, Clermont-Ferrand
- Study coordinator: Lise Laclautre
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: 0033473754027
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote electrical neuromodulation to test pain inhibition in migraine and fibromyalgia
We’re testing if the Nerivio wearable can boost the body’s natural pain-inhibition system (CPM) and reduce pain more than a sham device in adults with migraine or fibromyalgia.
-
Elismetrep (K-304) for acute treatment of migraine
This study tests whether a single dose of elismetrep can quickly lessen the pain of a migraine compared with placebo in adults 18 to 75.
-
Magnesium sulfate for acute non-traumatic headache in the ED: 2 g vs 4 g vs standard paracetamol
This study tests whether intravenous magnesium sulfate given in different doses helps adults with acute non-traumatic headache in the emergency department, compared with paracetamol.
-
HEADS Registry: Headache, Ear, Auditory, Dizziness, and Sinus</n> Registry
This registry tests whether collecting online symptom reports from adults in the U.S. with sinus, vestibular, ear, or headache symptoms can help improve diagnosis and treatment.
-
OCT in Neurological Practice: Use of Retinal Layers to Help Diagnose and Follow Neurological Diseases
This study tests whether optical coherence tomography (OCT) of the retina can help in diagnosing and tracking multiple sclerosis, Alzheimer's, Parkinson's, migraines, and other headaches compared with healthy people.
-
Online Hatha Yoga Add-On for High-Frequency Episodic Migraine
This trial tests whether a 12-week online Hatha yoga program added to usual migraine treatment can help adults with high-frequency episodic migraine.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.